Capital Fund Management S.A. Bio N Tech Se Call Options Transaction History

Capital Fund Management S.A.

$36 Billion
Q3 2024

Call Options

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$78.36 - $124.66 $1.68 Million - $2.68 Million	21,500 Added 212.87%	31,600 $3.75 Million
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $8.49 Million - $10.9 Million	-105,700 Reduced 91.28%	10,100 $811,000
Q1 2024 May 15, 2024	SELL	$88.96 - $112.35 $7.07 Million - $8.93 Million	-79,500 Reduced 40.71%	115,800 $10.7 Million
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $10.1 Million - $12.5 Million	111,000 Added 131.67%	195,300 $20.6 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $866,800 - $1.1 Million	-8,800 Reduced 9.45%	84,300 $9.16 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $7.81 Million - $9.87 Million	76,100 Added 447.65%	93,100 $10 Million
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $24,514 - $30,733	200 Added 1.19%	17,000 $2.12 Million
Q4 2022 Feb 13, 2023	SELL	$118.43 - $186.05 $378,976 - $595,360	-3,200 Reduced 16.0%	16,800 $2.52 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $229,770 - $329,598	1,800 Added 9.89%	20,000 $2.7 Billion
Q2 2022 Aug 12, 2022	SELL	$123.25 - $186.24 $2.54 Million - $3.84 Million	-20,600 Reduced 53.09%	18,200 $2.71 Million
Q1 2022 May 12, 2022	SELL	$126.25 - $231.85 $8.08 Million - $14.8 Million	-64,000 Reduced 62.26%	38,800 $6.62 Million
Q4 2021 Feb 10, 2022	BUY	$216.64 - $362.52 $7.21 Million - $12.1 Million	33,300 Added 47.91%	102,800 $26.5 Million
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $11.3 Million - $24.5 Million	54,800 Added 372.79%	69,500 $19 Million
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $1.67 Million - $3.55 Million	14,700 New	14,700 $3.29 Million

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.4M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.

Account